Alexza Pharmaceuticals, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Mountain View CA United States (2000)
Status: No NME R&D (2000)

Organization Overview

First Clinical Trial
2004
NCT00610727
First Marketed Drug
2012
loxapine (loxitane)
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Alexza Pharmaceuticals, Inc. | ALEXZA PHARMS

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 1)

Breakthrough Pain (Phase 1)

Cardiotoxicity (Phase 1)

Disease (Phase 3)

Epilepsy (Phase 2)

Headache (Phase 2)

Lung Diseases (Phase 1)

Lung Diseases, Obstructive (Phase 1)

Migraine Disorders (Phase 2)

Panic Disorder (Phase 2)

Parkinson Disease (Phase 1)

Psychomotor Agitation (Phase 3)

Pulmonary Disease, Chronic Obstructive (Phase 1)

Schizophrenia (Phase 3)

Syndrome (Phase 2)

Vomiting (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 30
  • # of Trial APIs: 12